A
bstract
We extend the coverage of resonant di-Higgs searches in the
b
b
¯
b
b
¯
final state to the process
pp → H
1
→ H
2
H
2
→ b
b
¯
b
b
¯
, where both
H
1
,
2
are spin-0 states beyond the ...Standard Model. Such a process constitutes a joint discovery mode for the new states
H
1
and
H
2
. We present the first sensitivity study of this channel, using public LHC data to validate our analysis. We also provide a first estimate of the sensitivity of the search for the HL-LHC and future facilities like the HE-LHC and FCC-hh. We analyze the discovery potential of this search for several non-minimal scalar sector scenarios: an extension of the SM with two extra singlet scalar fields, the two-Higgs-doublet model and a two-Higgs doublet model plus a singlet, which captures the scalar potential features of the NMSSM. We find that this channel represents a novel, very powerful probe for extended Higgs sectors, offering complementary sensitivity to existing analyses.
Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its impact on prognosis of young patients harboring BRCA ...pathogenic variant (PV).
This international, multicenter, retrospective cohort study included young patients (aged ≤40 years) diagnosed with invasive breast cancer and harboring germline PV in BRCA genes. We investigated the impact of hormone receptor status on clinical behavior and outcomes of breast cancer. Outcomes of interest disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS) were first investigated according to hormone receptor expression (positive versus negative), and then according to breast cancer subtype luminal A-like versus luminal B-like versus triple-negative versus human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
From 78 centers worldwide, 4709 BRCA carriers were included, of whom 2143 (45.5%) had hormone receptor-positive and 2566 (54.5%) hormone receptor-negative breast cancer.
Median follow-up was 7.9 years. The rate of distant recurrences was higher in patients with hormone receptor-positive disease (13.1% versus 9.6%, P < 0.001), while the rate of second primary breast cancer was lower (9.1% versus 14.7%, P < 0.001) compared to patients with hormone receptor-negative disease. The 8-year DFS was 65.8% and 63.4% in patients with hormone receptor-positive and -negative disease, respectively. The hazard ratio of hormone receptor-positive versus -negative disease changed over time for DFS, BCSS, and OS (P < 0.05 for interactions of hormone receptor status and survival time). Patients with luminal A-like breast cancer had the worst long-term prognosis in terms of DFS compared to all the other subgroups (8-year DFS: 60.8% in luminal A-like versus 63.5% in triple-negative versus 65.5% in HER2-positive and 69.7% in luminal B-like subtype).
In young BRCA carriers, differences in recurrence pattern and second primary breast cancer among hormone receptor-positive versus -negative disease warrant consideration in counseling patients on treatment, follow-up, and risk-reducing surgery.
•In young BRCA carriers, hormone receptor status did not appear to be a strong positive prognostic factor.•Patients with luminal A-like disease seem to have the worst DFS compared to all the other subtypes.•Personalized treatment, surveillance, and prevention strategies based on disease biology are recommended in young BRCA carriers.
This paper presents the design of a front-end circuit for monolithic active pixel sensors. The circuit operates with a sensor featuring a small, low-capacitance (< 2 fF) collection electrode and is ...integrated in the DPTS chip, a proof-of-principle prototype of 1.5 mm × 1.5 mm including a matrix of 32 × 32 pixels with a pitch of 15 μm. The chip is implemented in the 65 nm imaging technology from the Tower Partners Semiconductor Co. foundry and was developed in the framework of the EP-R&D program at CERN to explore this technology for particle detection. The front-end circuit has an area of 42 μm 2 and can operate with a power consumption as low as 12 nW. Measurements on the prototype relevant to the front-end will be shown to support its design.
The eighth annual conference of “Innovative therapy, monoclonal antibodies, and beyond” was held in Milan on Jan. 26, 2018, and hosted by Fondazione IRCCS–Istituto Nazionale dei Tumori (Fondazione ...IRCCS INT). The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets, and ii) clinical translation, as well as a third session of presentations from young investigators, which focused on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies. Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor heterogeneity, with key topics addressing: 1) tumor heterogeneity and targeted therapy, with the definition of the evolutionary Index as an indicator of tumor heterogeneity in both space and time; 2) the analysis of cancer evolution, with the introduction of the TRACERx Consortium—a multi-million pound UK research project focused on non-small cell lung cancer (NSCLC); 3) the use of anti-estrogen agents to boost immune recognition of breast cancer cells; and 4) the high degree of functional plasticity within the NK cell repertoire, including the expansion of adaptive NK cells following viral challenges. The second session addressed: 1) the effectiveness of radiotherapy to enhance the proportion of patients responsive to immune-checkpoint blockers (ICBs); 2) the use of MDSC scores in selecting melanoma patients with high probability to be responsive to ICBs; and 3) the relevance of the gut microbiome as a predictive factor, and the potential of its perturbation in increasing the immune response rate to ICBs. Overall, a picture emerged of tumor heterogeneity as the main limitation that impairs the effectiveness of anti-cancer therapies. Thus, the choice of a specific therapy based on reproducible and selective predictive biomarkers is an urgent unmet clinical need that should be addressed in order to increase the proportion of long-term responding patients and to improve the sustainability of novel drugs.
The study of associated boson production in the final state with a lepton, neutrino, and a bb-pair is important since the event topology of this process is the same as expected for associated ...production of a W and the Standard Model light-Higgs boson. Thus, the search for boson production can be considered as a preliminary step towards the Higgs discovery. Here we present a search for WZ/ZZ in events with a lepton, missing transverse energy, and b-quark jets. Besides looking at the sample where two exclusive jets are found, we investigate the sample with 3 jets which contains 40% of the signal events. In this sample the invariant mass of the two E sub(T)-leading jets would normally be chosen to signal the Z boson. We describe an alternative procedure to reconstruct the Z-invariant mass in this sample. This procedure exploits the information carried by the third jet in the sample.
PDF
